Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Molecular Pharmacology|September 5, 2008
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitorsRebecca S Y Wong, Veronique Bodart, Markus Metz, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 ReplicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphomaAmanda Cashen, Sandra Lopez, Feng Gao, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2011
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Leukemia Research|April 4, 2007
Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cellsJane L Liesveld, Jeremy Bechelli, Karen Rosell, et al.
Antimicrobial Agents and Chemotherapy|April 30, 2008
Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus compositionSigne Fransen, Gary Bridger, Jeannette M Whitcomb, et al.
Leukemia & Lymphoma|August 7, 2009
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and NilotinibFalk Dillmann, Marlon R Veldwijk, Stephanie Laufs, et al.
Immunity|October 18, 2003
Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescenceCoralie Martin, Peter C E Burdon, Gary Bridger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patientPatrick Stiff, Ivana Micallef, Philip McCarthy, et al.
Pharmacology & Therapeutics|July 13, 2005
The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary diseaseCory M Hogaboam, Kristin J Carpenter, Jane M Schuh, et al.
Pageof 6